LOS ANGELES, July 21, 2017 -- Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Weibo Corporation (“Weibo” or the “Company”) (Nasdaq:WB) for possible violations of federal securities laws between April 27, 2017 and June 22, 2017, inclusive (the “Class Period”). Investors who purchased or otherwise acquired Weibo shares during the Class Period should contact the firm prior to August 28, 2017, the lead plaintiff motion deadline.
To participate in this class action lawsuit, click here.
You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at [email protected].
No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may choose to do nothing and be an absent class member as well.
According to the Complaint, during the Class Period, Weibo made false and/or misleading statements and/or failed to disclose: that the Company lacks a required internet audio/video program transmission license; that Weibo was posting some commentary programs with content in violation of Chinese government regulations on its site; and that as a result of the above, the Company’s public statements were materially false and misleading at all relevant times. When this news reached the public, shares of Weibo fell in value materially, which caused investors harm according to the Complaint.
Lundin Law PC was established by Brian Lundin, Esq., a securities litigator in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in certain jurisdictions under the applicable law and rules of ethics.
Contact: Lundin Law PC Brian Lundin, Esq. Telephone: 888-713-1033 Facsimile: 888-713-1125 [email protected] http://lundinlawpc.com/


Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
FDA Approves Mitapivat for Anemia in Thalassemia Patients
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
Italy Fines Apple €98.6 Million Over App Store Dominance
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 



